TITLE

Other News To Note

PUB. DATE
October 2011
SOURCE
BioWorld International;10/26/2011, Vol. 16 Issue 43, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs on drug manufacturing. A Phase III trial of laquinimod by Sweden's Active Biotech AB and Jerusalem's Teva Pharmaceutical Industries Ltd. showed that it significantly reduced the relapse of multiple sclerosis. Danish drug manufacturer Affitech received 2.5 million Euros from Russia's IBC Generium for its anti-cancer antibody AT001/r84. A 4-year grant was received by Austria's Arsanis Biosciences GmbH to develop monoclonal antibodies against nosocomial infections.
ACCESSION #
66862208

 

Related Articles

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: Monthly Review;Jul2007, Vol. 6 Issue 7, p15 

    The article reports on the positive result of the test of laquinimod, an oral disease modifying treatment for multiple sclerosis. Phase III clinical trials are initiated by Teva and Swedish biotech partner Active Biotech AB. It is stated that laquinimod is expected to become the fifth oral...

  • Teva and Active Biotech complete enrollment for Phase III MS trial.  // PharmaWatch: Biotechnology;Jan2009, Vol. 8 Issue 1, p4 

    The article reports on the patient enrollment completed by Teva Pharmaceuticals Industries Ltd. and Active Biotech AB for the Phase II clinical trial, Allegro in the U.S. The pivotal Allegro study is designed to evaluate the efficacy, safety and tolerability of the oral investigational compound,...

  • Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p121 

    The article reports on the presentation of data from a study conducted by Teva Pharmaceutical Industries Ltd. and Active Biotech AB on the potential of laquinod in treating multiple sclerosis. The findings of the phase III study suggests the effectiveness of laquinimod in reducing annualized...

  • Teva and Active Biotech announce fast track status for multiple sclerosis drug.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p12 

    The article reports on the announcement made by Teva Pharmaceutical Industries, a generic pharmaceutical company and Sweden-based pharmaceutical company Active Biotech on the fast track designation given by the Food and Drug Administration to the oral laquinimod in the U.S. It cites that oral...

  • Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article informs that Teva Pharmaceutical Industries Ltd. and Active Biotech AB are to initiate a third Phase III study of laquinimod, following the written agreement reached with the U.S. Food & Drug Administration (FDA) on the Special Protocol Assessment (SPA). The third Phase III...

  • Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis.  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    The article presents information on the clinical development program of once-daily oral laquinimod from Teva Pharmaceutical Industries Ltd. and Active Biotech AB for the treatment of relapsing-remitting multiple sclerosis (RRMS). The companies are going to start a third Phase III trial of...

  • Teva and Active Biotech amend marketing and distribution agreement.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p5 

    No abstract available.

  • Teva, Active Down Following Laquinimod Phase III Miss. Wall, Tom // BioWorld Today;8/2/2011, Vol. 22 Issue 148, p1 

    The article reports on the decline in stocks of pharmaceutical companies Active Biotech AB and Teva Pharmaceutical Industries Ltd. It states that the decline came as a result of the announcement that laquinimod, an oral multiple sclerosis drug, failed to decrease the annualized relapse rate in...

  • CNS News Round-Up.  // PharmaWatch: CNS;Oct2012, Vol. 11 Issue 10, p2 

    The article offers a news round-up about the biopharmaceutical industry. Drug company Teva Pharmaceutical Industries and biotechnology firm Active Biotech will be starting a third Phase II study of laquinimod to treat relapsing-remitting multiple sclerosis (RRMS). Biopharmaceutical firm Shire...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics